These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 16948200)

  • 1. [Oral hypoglycemic agents, present and future].
    Shimano H
    Nihon Yakurigaku Zasshi; 2006 Jul; 128(1):42-5. PubMed ID: 16948200
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c.
    Ferré P; Foufelle F
    Diabetes Obes Metab; 2010 Oct; 12 Suppl 2():83-92. PubMed ID: 21029304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
    Onuchin SG; Elsukova OS; Solov'ev OV; Onuchina EL
    Ter Arkh; 2010; 82(8):34-41. PubMed ID: 20873243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Approach to diabetes therapy. 2. Selection and the use of oral antidiabetics. 2) Agents to correct insulin resistance].
    Kashiwagi A; Maegawa H
    Nihon Naika Gakkai Zasshi; 2000 Aug; 89(8):1530-5. PubMed ID: 11062900
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical efficacy of Pioglitazone (AD-4833)].
    Kaneko T; Baba S
    Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rosiglitazone (BRL-49653)].
    Oka Y
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral hypoglycaemic agents in the treatment of immunogenic insulin resistance in NIDDM.
    Ramachandran A; Snehalatha C; Mohan V; Rao CA; Viswanathan M
    Diabete Metab; 1987 Apr; 13(2):140-1. PubMed ID: 3595969
    [No Abstract]   [Full Text] [Related]  

  • 8. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
    Lotz N
    MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of moderate aerobic exercise training on insulin sensitivity in type 2 diabetic men treated with oral hypoglycemic agents: is insulin sensitivity enhanced only in non-obese subjects?
    Bense L
    Med Sci Monit; 2002 Jun; 8(6):LE23; discussion L24. PubMed ID: 12134782
    [No Abstract]   [Full Text] [Related]  

  • 10. Initiating insulin in type 2 diabetes.
    Ravina A
    Isr Med Assoc J; 2004 Dec; 6(12):787. PubMed ID: 15609901
    [No Abstract]   [Full Text] [Related]  

  • 11. Insulin therapy for type 2 diabetes.
    Pergallo-Dittko V
    Diabetes Self Manag; 2003; 20(5):17, 21, 23-4. PubMed ID: 14679948
    [No Abstract]   [Full Text] [Related]  

  • 12. Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents.
    Hanyu O; Miida T; Kosuge K; Ito T; Soda S; Hirayama S; Wardaningsih E; Fueki Y; Obayashi K; Aizawa Y
    Clin Chim Acta; 2007 Sep; 384(1-2):118-23. PubMed ID: 17651713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin sensitizers.
    Das S
    J Assoc Physicians India; 1997; Suppl 1():32-6. PubMed ID: 11235632
    [No Abstract]   [Full Text] [Related]  

  • 14. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
    Patsouris D; Müller M; Kersten S
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Escaping oral hypoglycemic agents in type 2 diabetes: importance and limitations of transitory optimized insulin therapy].
    Leutenegger M; Bertin E; Grulet H
    Diabetes Metab; 1998 Feb; 24(1):80-4. PubMed ID: 9534015
    [No Abstract]   [Full Text] [Related]  

  • 16. [First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated].
    MMW Fortschr Med; 2000 Sep; 142(36):50. PubMed ID: 11021073
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral hypoglycemic agents and metformin in the treatment of type II non-insulin-dependent diabetes].
    Isnard F
    Sem Hop; 1983 Dec; 59(49):3437-8. PubMed ID: 6320423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes.
    Darmon P; Curtillet C; Boullu S; Laugier A; Dutour A; Oliver C
    Diabetes Care; 1998 Sep; 21(9):1575. PubMed ID: 9727917
    [No Abstract]   [Full Text] [Related]  

  • 20. New advances in the management of insulin resistance in type 2 diabetes. Introduction.
    Campbell IW; Charbonnel B
    Int J Clin Pract Suppl; 2001 Sep; (121):3. PubMed ID: 11594242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.